BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND JUN, P05412, 3725, ENSG00000177606, AP1, c-Jun AND Treatment
48 results:

  • 1. MMPs-related risk model identification and SAA1 promotes clear cell renal cell carcinoma migration via ERK-ap1-MMPs axis.
    Wei H; Li Y; Zhang J; Xu C; Wei D; Quan C; Zhu S
    Sci Rep; 2024 Apr; 14(1):9411. PubMed ID: 38658579
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Unveiling the hidden AP-1: revealing the crucial role of AP-1 in ccRCC at single-cell resolution.
    Zheng J; Liu F; Su C
    Mol Cancer; 2023 Dec; 22(1):209. PubMed ID: 38114996
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Quantitative Phosphoproteomics Analysis Uncovers PAK2- and CDK1-Mediated Malignant Signaling Pathways in Clear Cell Renal Cell Carcinoma.
    Senturk A; Sahin AT; Armutlu A; Kiremit MC; Acar O; Erdem S; Bagbudar S; Esen T; Ozlu N
    Mol Cell Proteomics; 2022 Nov; 21(11):100417. PubMed ID: 36152754
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Telmisartan-Induced Cytotoxicity via G
    Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
    Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Leptin Is Associated with Poor Clinical Outcomes and Promotes Clear Cell Renal Cell Carcinoma Progression.
    Fan WL; Yeh YM; Liu TT; Lin WM; Yang TY; Lee CW; Lin TC
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33804101
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Inhibitors of TGFβR1/ALK4/JNK3/Flt1 Kinases in Cynomolgus Macaques Lead to the Rapid Induction of Renal Epithelial tumors.
    Carreira V; Standeven AM; Ma JY; Hardisty J; Cohen SM; Kerns WD; Snook S
    Toxicol Sci; 2021 Feb; 180(1):51-61. PubMed ID: 33483736
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Norcantharidin induces G2/M arrest and apoptosis via activation of ERK and JNK, but not p38 signaling in human renal cell carcinoma ACHN cells.
    Huang S; Tuergong G; Zhu H; Wang X; Weng G; Ren Y
    Acta Pharm; 2021 Jun; 71(2):267-278. PubMed ID: 33151174
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification of an ap1-ZFP36 Regulatory Network Associated with Breast Cancer Prognosis.
    Canzoneri R; Naipauer J; Stedile M; Rodriguez Peña A; Lacunza E; Gandini NA; Curino AC; Facchinetti MM; Coso OA; Kordon E; Abba MC
    J Mammary Gland Biol Neoplasia; 2020 Jun; 25(2):163-172. PubMed ID: 32248342
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MCP-1/MCPIP-1 Signaling Modulates the Effects of IL-1β in Renal Cell Carcinoma through ER Stress-Mediated Apoptosis.
    Lee CH; Hung PF; Lu SC; Chung HL; Chiang SL; Wu CT; Chou WC; Sun CY
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816951
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-jun Signaling in Renal Cancer.
    Ma G; Liang Y; Chen Y; Wang L; Li D; Liang Z; Wang X; Tian D; Yang X; Niu H
    Mol Cancer Res; 2020 Feb; 18(2):324-339. PubMed ID: 31672701
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. LncRNA SCAMP1 regulates ZEB1/jun and autophagy to promote pediatric renal cell carcinoma under oxidative stress via miR-429.
    Shao Q; Wang Q; Wang J
    Biomed Pharmacother; 2019 Dec; 120():109460. PubMed ID: 31550675
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Early assessment with
    Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
    BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Multiple Targets of 3-Dehydroxyceanothetric Acid 2-Methyl Ester to Protect Against Cisplatin-Induced Cytotoxicity in kidney Epithelial LLC-PK1 Cells.
    Lee D; Kim KH; Lee WY; Kim CE; Sung SH; Kang KB; Kang KS
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30832267
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.
    Zeng Y; Tian X; Wang Q; He W; Fan J; Gou X
    Drug Des Devel Ther; 2018; 12():911-920. PubMed ID: 29719377
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Inhibition of Intracellular ROS Accumulation by Formononetin Attenuates Cisplatin-Mediated Apoptosis in LLC-PK1 Cells.
    Lee H; Lee D; Kang KS; Song JH; Choi YK
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534504
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Protein extracted from Porphyra yezoensis prevents cisplatin-induced nephrotoxicity by downregulating the MAPK and NF-κB pathways.
    Kim IH; Kwon MJ; Jung JH; Nam TJ
    Int J Mol Med; 2018 Jan; 41(1):511-520. PubMed ID: 29115386
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-jun Activation in Renal Cell Carcinoma.
    Kim C; Lee JH; Baek SH; Ko JH; Nam D; Ahn KS
    Phytother Res; 2017 Jul; 31(7):1078-1089. PubMed ID: 28544385
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 jun 8]. doi: 10.1002/cncr.29503.
    Jay R; McKay RR; Werner L; Atkins MB; Van Allen EM; Olivier KM; Song J; Signoretti S; McDermott DF; Choueiri TK
    Urol Oncol; 2017 Mar; 35(3):117-118. PubMed ID: 28159495
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.